NORFLOXACIN FOR THE PROPHYLAXIS OF TRAVELERS' DIARRHEA IN U.S. MILITARY PERSONNEL

BY

Daniel A. Scott, Richard L. Haberberger, Scott A. Thornton and Kenneth C. Hyams

U.S. NAVAL MEDICAL RESEARCH UNIT NO. 3
(cairo, arab republic of egypt)
FPO new york 09527

91-12593
NORFLOXACIN AND TRAVELERS' DIARRHEA

Table 1

Comparison of demographic factors between norfloxacin and placebo groups

<table>
<thead>
<tr>
<th>Factor (mean ± SD)</th>
<th>Placebo (n = 117)</th>
<th>Norfloxacin (n = 105)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>26.1 ± 6.9</td>
<td>26.5 ± 9.9</td>
<td>0.71</td>
</tr>
<tr>
<td>Days ashore</td>
<td>2.8 ± 0.9</td>
<td>2.9 ± 0.9</td>
<td>0.16</td>
</tr>
<tr>
<td>Days in Cairo</td>
<td>1.3 ± 0.7</td>
<td>1.4 ± 0.6</td>
<td>0.62</td>
</tr>
<tr>
<td>Days in Alexandria</td>
<td>1.4 ± 1.1</td>
<td>1.6 ± 1.2</td>
<td>0.35</td>
</tr>
<tr>
<td>No. completing study/No. enrolled</td>
<td>117/138</td>
<td>105/124</td>
<td>0.99</td>
</tr>
<tr>
<td>History of previous travel to Egypt</td>
<td>13/116</td>
<td>5/104</td>
<td>0.14</td>
</tr>
<tr>
<td>Positive pre-treatment culture</td>
<td>3/69</td>
<td>4/60</td>
<td>0.85</td>
</tr>
</tbody>
</table>

Cary-Blair transport media and cultured at the Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt, after a maximum storage period of 5 days. Acute stool specimens from subjects with diarrhea were cultured immediately after collection in a laboratory established on the ship. Standard bacteriological methods were used to culture Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter spp., Vibrio spp., Aeromonas hydrophila group, and Plesiomonas shigelloides.

When present on the initial culture, 5 colonies of E. coli were selected and frozen at -20°C. Each was assayed for heat labile (LT) and heat stable (ST) enterotoxin using commercially available DNA probes (DuPont, Wilmington, DE). Enteropathogenic E. coli strains (EAEC) were identified by adherence to HEp-2 cells in the presence of D-mannose. 

Slide agglutination (Bio-Merieux, France) was used to identify enteropathogenic E. coli strains (EPEC) and all colonies that were sorbitol negative on Sorbitol-MacConkey agar were serotyped with 0:157 antiserum to screen for enterohemorrhagic E. coli (EHEC) (DIFCO Labs, Detroit, MI). All E. coli that were initially lysine decarboxylase negative and nonmotile were further investigated for enteroinvasiveness by the Sereny test.

The presence of protozoa and helminthic parasites was assessed by direct microscopic examination of fresh stool and specimens prepared by merthiolate-iodine-formalin concentration (MIFC). Methanol-fixed smears were stained with a modified acid fast stain and examined for Cryptosporidium oocysts. Stools were also examined for rotavirus by an enzyme-linked immunosorbent assay (Rotazyme, Abbott Laboratories).

Statistical analysis was performed using SPSS/PC+ statistical package (SPSS Inc., Chicago, IL). The chi-square test with Yates correction was used for proportions; the Student's t-test was used for comparison of means. Mean values were reported as ± 1 SD. Efficacy of the drug was calculated as follows: [(percent ill in placebo group − percent ill in drug group)/percent ill in placebo group] × 100.

RESULTS

Initially, 262 volunteers were enrolled in the study. Of these, 20 did not return for medication, 15 withdrew prior to reaching Alexandria or took no pills, 2 transferred from the ship, 2 did not respond to attempts at follow-up, and 1 went on emergency leave, making a total of 40 volunteers who did not complete the study. A total of 222 remained for analysis.

Pre-treatment stools were submitted by 129 of the subjects completing the study. The number of these pre-treatment stools positive for enteric pathogens in the placebo and norfloxacin groups were not statistically different (3/69 vs. 4/60, respectively). Pre-Alexandria positive cultures included 5 enterotoxigenic E. coli (ETEC) (3-LT+, 2-LT+/ST+) and 2 EAEC. None of the subjects with positive pre-treatment stools developed diarrhea.

As noted in Tables 1 and 2, there were no differences between the placebo and norfloxacin groups in terms of age, days ashore, number of meals, or types of foods eaten. Most subjects enrolled in the study made an organized excursion to Cairo as well as day trips to Alexandria. The frequency of compliance and side effects did not differ between the groups. Subjects in the norfloxacin and placebo groups reported missing a mean of 0.5 ± 1.1 and 0.2 ± 0.8 doses, respectively (P = 0.07). Side effects were reported in 2.7% of the placebo group and 4% of the norfloxacin group (P = 0.9). There were 2 reports...
of headache and 1 report each of dizziness, urinary symptoms, constipation, nausea, and localized rash. None of these were clinically significant or required discontinuation of the medication.

Norfloxacin gave significant protection against the development of acute diarrhea. Diarrhea developed in 25.6% (30/117) of the placebo group vs. 1.9% (2/105) of the norfloxacin group (93% protective efficacy). Compliance was a problem for the 2 study subjects in the norfloxacin group who developed diarrhea. One reported a single day of diarrhea after missing a dose of medication. He did not report for follow-up at the time of his illness, but submitted a normal stool 8 days after the diarrheal episode from which no enteric pathogen was isolated. The other subject reported missing medication for 2 days prior to developing diarrhea; this subject submitted no stool specimen.

Of the 32 who developed diarrhea, 1 norfloxacin and 17 placebo subjects submitted acute stool samples. Nine of these were positive for an enteric pathogen (Table 3). The majority of isolates were either enterotoxigenic E. coli or Campylobacter. A single stool contained both Campylobacter and rotavirus. All of the bacterial isolates were sensitive to norfloxacin.

DISCUSSION

Norfloxacin was effective for the short term prophylaxis of acute diarrhea in U.S. Naval and Marine Corps personnel on shore leave in Egypt. Comparable demographic and epidemiologic data between the treatment and control groups indicate that both groups were at a similar risk of infection. The failures occurred in subjects who did not comply with the study regimen.

This study confirms findings in Mexico that norfloxacin is effective taken once daily as compared to the twice daily regimen used in Swedish travelers. It also supports norfloxacin's efficacy among different study populations and in different areas of the world.

There were no serious clinical side effects. This may in part be due to the short duration of the study, although norfloxacin has been generally well tolerated even when given for up to 6 weeks for treatment of urinary tract infections. In 2 longer prophylaxis trials with norfloxacin, side effects were minimal.

The antimicrobial agents doxycycline and trimethoprim-sulfamethoxazole (TMP-SMX) have undergone extensive evaluation as diarrhea prophylactic agents. Doxycycline is effective in areas where most of the isolates are sensitive, but the efficacy decreases in areas where enterotoxigenic E. coli are resistant. Doxycycline resistant E. coli strains develop during therapy. In addition, a recent study of U.S. Army personnel in Thailand who were taking doxycycline for malaria prophylaxis identified doxycycline-resistant Campylobacter as the etiologic agent in 30% of the diarrhea cases.

Resistance to norfloxacin does not develop as rapidly as with nalidixic acid. Point mutations leading to increased MICs occur at a very low frequency, and although serial passage in the presence of the drug has lead to high-level resistance, norfloxacin inhibits the transfer of plasmids that may mediate resistance. However, an isolate of Shigella dysenteriae with plasmid mediated resistance to nalidixic acid has been reported. During a previous prophylaxis trial with norfloxacin, resistant bacteria were not observed.

Antibiotic prophylaxis in this study was effective, but the question of whether to use antibiotics for prevention remains controversial. Dietary measures are the simplest and safest methods of prevention, but it has been difficult.
to show that these measures are effective. The benefits of prophylaxis must be weighed against the potential side effects for the individual and against the global concern of emerging resistant organisms. Consequently, antibiotic prophylaxis may be appropriate only for selected populations who have a special reason to avoid developing acute diarrhea. Norfloxacin may have some advantages in terms of the spectrum of antibacterial activity, infrequent side effects, and a lower potential for development of resistant bacteria. Most individuals, however, have a rapid response to therapy when treated soon after symptoms develop, and do not require prophylaxis.

Acknowledgments: The authors wish to thank John McHugh, Senior Medical Officer, USS John F. Kennedy, for his assistance in completing this study; Isis Mikhail for E. coli analysis; Steven Martinez, John Williams, Tharwat Ismail, and Cecilia Callahan for technical assistance; and Nancy Scott and Jack Watkins for data entry.

Financial support: The Naval Medical Research and Development Command, NMC, NCR, Bethesda, MD, is of travelers' diarrhea with norfloxacin.

TABLE 3

Etiologic agents identified in acute stool specimens of subjects with diarrhea

<table>
<thead>
<tr>
<th>Organism identified</th>
<th>Study group</th>
<th>Placebo (n = 20)</th>
<th>Norfloxacin (n = 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETEC</td>
<td></td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Campylobacter</td>
<td></td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>EAEC</td>
<td></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Entamoeba histolytica</td>
<td></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>None</td>
<td></td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>No stool submitted</td>
<td></td>
<td>13</td>
<td>1</td>
</tr>
</tbody>
</table>

REFERENCES


15. Taylor DN, Pittarangsi C, Escheverria F, Dinega BM, 1988. Campylobacter enteritis during dox-
164

SCOTT AND OTHERS

...cycline prophylaxis for malaria in Thailand. Lancet 2: 578–579. UI:88317914
Norfloxacin for the Prophylaxis of Travelers' Diarrhea in U.S. Military Personnel.

Norfloxacin, an oral fluoroquinolone (dose 400 mg daily), was compared to a placebo in a double blinded randomized trial for the prophylaxis of travelers' diarrhea. The study was of U.S. Navy and Marine Corps personnel on shore leave in Alexandria, Egypt. A total of 222 subjects were available (105 norfloxacin, 117 placebo). In the placebo group, 26% (30/117) developed acute diarrhea vs. 2% (1/105) in the norfloxacin group. There were no significant side effects in either group.

* U.S. Naval Medical Research Institute, Bethesda, Maryland.